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ackground: Allergic rhinitis (AR) poses a signiﬁcant global burden with increasing prevalence. Although
tranasal glucocorticosteroids are effective, older agents can have limiting side effects. S0597, a novel intranasal
lucocorticosteroid, has demonstrated good safety and tolerability during preclinical and phase 1 studies.
bjective: To assess the clinical efﬁcacy, safety, and tolerability of different doses of S0597 nasal spray vs
placebo in patients with seasonal AR.
Methods: This phase 2, randomized, double-blinded, placebo-controlled, parallel-group, single-center study
randomized 159 patients 18 to 65 years old (mean age 37.8 years) with a positive skin prick test reaction for
Dactylis glomerata to receive S0597 at 200, 400, or 800 mg/d or placebo for 15 days. On days 1 (baseline), 15,
and 16, patients underwent a 4-hour pollen challenge to evaluate treatment efﬁcacy measured by the
change in total nasal symptom score (TNSS) from baseline to days 15 and 16 and changes in TNSS subscales
and nasal secretion.
Results: Statistically signiﬁcant improvements in TNSS from baseline to days 15 and 16 were observed with
all S0597 doses vs placebo (P ¼ .0005 overall), with the greatest improvements observed in the highest-dose
group (P < .0001). Signiﬁcant decreases were observed in each S0597 dose group vs placebo for TNSS
subscales and nasal secretion. Improvements in nasal secretion were related to dose, with the greatest
decreases from baseline in the 800-mg/d group on days 15 and 16 (P < .0001).
Conclusion: Treatment with S0597 at 200, 400, and 800 mg/d by 2 divided doses for 2 weeks was safe and
signiﬁcantly more effective than placebo for improving nasal symptoms associated with grass pollen-
induced seasonal AR in adults.
Trial Registration: ClinicalTrials.gov, identiﬁer NCT01614691.
 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction S0597 is a novel INS developed by the Sun Pharma AdvancedAllergic rhinitis (AR) is a signiﬁcant public health concern affecting
an estimated 500 million people globally.1,2 Intranasal glucocorticos-
teroids (INSs) are regarded as the most effective pharmacologic
treatment for AR and are recommended by the Allergic Rhinitis and its
Impact on Asthma guidelines as ﬁrst-line treatment.2,3 INSs have a
good safety proﬁle, with a low risk of systemic side effects owing to
their low systemic bioavailability.4 This is especially true for newer
INSs, suchas ciclesonide,mometasone furoate, andﬂuticasone furoate,
which have a systemic bioavailability lower than 1%.5itute for Toxicology and Experi-
nover, Germany; E-mail: philipp.
Sun Pharma Advanced Research
nﬂicts of interest.
rch Company Ltd and Fraunhofer
ne.
sthma & Immunology. Published by EResearch Company Ltd (Mumbai, India). S0597 has potent gluco-
corticoid receptor binding (in the nanomolar range) and low
binding afﬁnity to other sex steroid receptors (including proges-
terone, estrogen receptors [ERa and ERb], and testosterone) and
aldosterone.6 In preclinical models, S0597 showed local
anti-inﬂammatory activity, low oral bioavailability, and low
potential for systemic adverse effects, leading to a high thera-
peutic index.6 Its elimination proﬁle, pronounced binding to
plasma protein and erythrocytes, and low oral bioavailability
make it a suitable candidate for topical use.6 S0597 has shown a
favorable safety proﬁle in preclinical and phase 1 clinical devel-
opment (data on ﬁle, Sun Pharma Advanced Research Company).
The aim of this study was to assess the clinical efﬁcacy, safety, and
tolerability of 3 twice-daily doses (100, 200, and 400 mg) of S0597
nasal spray compared with placebo in an environmental challenge
chamber (ECC) in patients with seasonal AR (SAR). The ECC is an
accepted model for testing anti-allergic treatment in early clinicallsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Baseline characteristics and reasons for discontinuation (safety population)
Characteristic S0597 Placebo (n ¼ 40) Total (n ¼ 159)
200 mg/d (n ¼ 39) 400 mg/d (n ¼ 40) 800 mg/d (n ¼ 40)
Age (y), mean (SD) 39.0 (11.4) 37.2 (9.5) 37.2 (11.5) 37.9 (12.1) 37.8 (11.1)
Height (cm), mean (SD) 175.4 (7.4) 178.3 (7.8) 174.1 (9.0) 175.4 (9.7) 175.8 (8.6)
Weight (kg), mean (SD) 78.7 (18.0) 78.6 (14.3) 74.9 (13.3) 79.7 (12.1) 77.9 (14.5)
Sex, n (%)
Men 20 (51.3) 26 (65.0) 19 (47.5) 22 (55.0) 87 (54.7)
Women 19 (48.7) 14 (35.0) 21 (52.5) 18 (45.0) 72 (45.3)
White race, n (%) 39 (100.0) 40 (100.0) 40 (100.0) 40 (100.0) 159 (100.0)
Discontinuation of study, n (%) 0 (0.0) 4 (10.0) 2 (5.0) 1 (2.5) 7 (4.4)
AE 0 (0.0) 4 (10.0) 1 (2.5) 1 (2.5) 6 (3.8)
Other 0 (0.0) 0 (0.0) 1 (2.5) 0 (0.0) 1 (0.6)
Abbreviation: AE, adverse event.
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control environmental conditions, such as temperature, humidity, and
allergen concentration. As a result, fewer participants are necessary to
show signiﬁcant treatment effects than would be required for a ﬁeld
study. Numerous clinical trials in Europe, North America, and Japan
have used ECCs to test anti-allergic treatment, including INS.8e16Methods
Study Design
This was a phase 2, randomized, double-blinded, placebo-
controlled, single-center, 4-arm, parallel study conducted at the
Fraunhofer Institute for Toxicology and Experimental Medicine
(Hannover, Germany). Adults with SAR were repeatedly exposed to
grass pollen (Dactylis glomerata; Allergon AB, Ängelholm, Sweden)
in the ECC (4,000 grains/m3). The concentration of pollen in the ECC
was closely monitored and stable for the duration of the
challenges.12
The study was performed from July to November 2012 (the ﬁrst
subject was enrolled on July 9, 2012 and the last subject completed
the study on November 2, 2012). Therefore, the study began after
the peak of the grass pollen season in Germany (which occurs in
May or June). After a screening visit, including a 2-hour screening
pollen challenge, the patients attended a 4-hour baseline pollen
challenge on day 1, after which each patient received S0597 at a
dose of 200 mg/d (100 mg twice daily), 400 mg/d (200 mg twice daily),
or 800 mg/d (400 mg twice daily) or placebo as a nasal spray
(morning and evening) for 15 days (days 1e15). On day 1, the pa-
tients received the morning dose after the challenge under the
supervision of an investigator and took the evening dose at home as
late as possible. On days 2 to 14, the patients were self-dosed twice
a day, morning and evening, with approximately 12 hours between
doses (patients were instructed to adhere to a 12-hour dosing cycleTable 2
Change in TNSS from baseline to day 15 and day 16 (intent-to-treat population)
S0597
200 mg/d (n ¼ 39) 400
Baseline TNSS, mean (SD) 5.8 (1.62) 6
Change from baseline to day 15, LSM (SE) 2.49 (0.268) 2.6
Change from baseline to day 16, LSM (SE) 1.97 (0.284) 2.0
P value for pairwise comparisona .0025 .001
Change from baseline to day 15 and day 16 (%)
Day 15, n 39 37
Change from baseline (%), mean (SD) 37.6 (34.05) 45
Day 16, n 39 36
Change from baseline (%), mean (SD) 32.0 (31.23) 35
Abbreviations: LSM, least-squares mean; TNSS, total nasal symptom score.
aSigniﬁcant paired treatment difference vs placebo (by the Student t test).whenever possible). On days 15 and 16, a 4-hour pollen challenge
was performed to evaluate treatment efﬁcacy. On day 15, the pa-
tients received the morning dose 30 minutes before the challenge
and took the last treatment dose at home in the evening, 12 hours
before the day 16 challenge.
After each challenge, patients were provided with a terbutaline
Turbohaler (Bricanyl Turbohaler, AstraZeneca, London, United
Kingdom) as rescue medication. Patients were instructed to use
rescue medication if there was a decrease of at least 20% in lung
function.
This study was approved by the local competent authority and
the ethics committee of the Hannover Medical School (Hannover,
Germany). It was conducted in accordance with the Declaration of
Helsinki (Somerset West Amendment, 1996) and the International
Conference on Harmonisation Guidelines on Good Clinical Practice.
Written informed consent was obtained from all study participants,
the consent form for which had been approved by the ethics
committee. The ClinicalTrials.gov identiﬁer is NCT01614691.
Patients
Patients were 18 to 65 years old and had a history of SAR from
grass pollen; a positive skin prick test reaction to D glomerata
within 12 months before enrollment; a total nasal symptom score
(TNSS) of at least 6 during a 2-hour screening challenge in the ECC;
forced expiratory volume in 1 second greater than 80% predicted;
and were nonsmoking for at least 12 months before enrollment,
with a smoking history shorter than 10 pack-years.
The main exclusion criteria included a history or the presence of
perennial AR; clinically signiﬁcant nasal septum deformation or nasal
polyps; respiratory tract infectionwithin 2weeksbefore the screening
challenge; pulmonary disease other than mild intermittent asthma
controlled by using b2-agonists alone; history of cataract, glaucoma, or
ocular hypertension; anti-allergy immunotherapy within 2 yearsPlacebo (n ¼ 39) P value
mg/d (n ¼ 37) 800 mg/d (n ¼ 39)
.3 (1.67) 6.1 (1.72) 5.5 (1.80) d
1 (0.276) 2.75 (0.268) 1.72 (0.270) .0005
3 (0.298) 2.49 (0.288) 0.56 (0.286) .0005
6 <.001 d d
39 39 d
.1 (25.42) 45.7 (27.93) 25.2 (34.07)
38 39 d
.0 (29.59) 41.8 (29.70) 2.9 (43.47)
Figure 1. Total nasal symptom score (TNSS) for the intent-to treat population.
*P < .05 vs placebo.
Figure 2. Effect of treatment on nasal secretion in the intent-to treat population.
*P < .0001 vs placebo.
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before screening; treatment with oral H1 antihistamines, cromogly-
cates, leukotrienemodiﬁers, or topical decongestants within 72 hours
before screening; treatmentwith a b-blocker or othermedication that
might interfere with rescue medication for allergic shock within 1
week before screening; and participation in another clinical trial
within 30 days before screening.
Before screening, there was a 4-week washout period for sys-
temic, topical, nasal, and inhaled corticosteroids, with a 72-hour
washout for H1 antihistamines, cromoglycates, leukotriene modi-
ﬁers, and topical decongestants.
Assessments
Nasal symptoms
The primary efﬁcacy end point was change in TNSS from base-
line to days 15 and 16. Nasal symptoms (congestion, rhinorrhea,
sneezing, itching) were self-assessed before and every 20 minutes
throughout the allergen challenge in the ECC. For each symptom,
patients recorded scores according to the following 4-point severity
scale: 0 ¼ none; 1 ¼mild; 2 ¼moderate; 3 ¼ severe. The TNSS was
calculated by adding the scores of the 4 individual nasal subscales.
Change in TNSS subscales from baseline to days 15 and 16
comprised the secondary efﬁcacy end point.
Nasal secretion
Change in nasal secretion frombaseline to days 15 and 16was an
additional secondary end point and determined using pre-weighed
paper tissues. Used and unused tissues were saved in a plastic bag
by each patient and collected every 60 minutes. The amount of
nasal secretion was determined by weighing the paper tissues.
Safety
Safety was assessed as the incidence and intensity of adverse
events (AEs), vital signs (pulse rate and blood pressure), lung
function (forced expiratory volume in 1 second), and physical
examination.
Statistical Analyses
Approximately 320 patients were planned to be screened to
randomize 160 patients to the study. The following populations
were analyzed.
Safety populationdall randomized patients receiving at least 1
dose of the study treatment or placebo.Intent-to-treat populationdall patients who were randomized
and received at least 1 dose of the study treatment and had baseline
and at least 1 post-baseline efﬁcacy assessments.
Per-protocol (PP) populationdall patients who completed the
study without any major protocol deviations.
The primary and secondary efﬁcacy analyses were conducted for
the intent-to-treat population using the last observation carried
forward method. Least-squares mean changes in TNSS, TNSS sub-
scales, and nasal secretion from baseline to days 15 and 16 were
compared among groups using repeated-measures analysis of
covariance, with treatment, visit, and treatment-by-visit interac-
tion as ﬁxed effects and baseline value as the covariate (treatment
comparison at the 2-sided .05 signiﬁcance level). Pairwise treat-
ment comparisons of each dose of S0597 vs placebo also were
conducted using the Student t test. All statistical analysis was
performed using SAS 9.2 or subsequent versions (SAS Institute,
Cary, North Carolina).
A supportive analysis for the primary and secondary end points
was performed for the PP population.
Results
Study Population
A total of 159 patients (mean age 37.8 years; 54.7% men; 99.4%
white) were randomized to receive study medication. All patients
had a positive skin prick test reaction to D glomerata. Baseline
characteristics are listed in Table 1.
Altogether, 152 patients (95.6%) completed the study. Seven
patients discontinued the study (6 [3.8%] owing to AEs; 1 [0.6%]
withdrew voluntarily). In total, 154 patients were included in the
intent-to-treat population.
Nasal Symptoms
Mean TNSS scores at baseline were 5.8 in the S0597
200-mg/d group, 6.3 in the 400-mg/d group, 6.1 in the 800-mg/
d group, and 5.5 in the placebo group (Table 2). For the primary
efﬁcacy end point, there was a statistically signiﬁcant improve-
ment in TNSS in all active treatment groups vs placebo from
baseline to days 15 and 16 (P¼ .0005 overall; Table 2, Fig 1). Mean
percentage decreases in TNSS from baseline to day 15 were in the
range of 38% to 46% in the active treatment groups comparedwith
Table 3
Summary of AEs (safety population)
S0597 Placebo (n ¼ 40)
200 mg/d (n ¼ 39) 400 mg/d (n ¼ 40) 800 mg/d (n ¼ 40)
AEs, n (%) 32 (23.1) 28 (19.3) 46 (31.7) 39 (26.9)
Serious AEs, n (%) 0 1 (0.7) 0 0
AEs leading to death, n (%) 0 0 0 0
AEs leading to permanent discontinuation of study drug, n (%) 0 3 (2.1) 1 (0.7) 1 (0.7)
AEs leading to withdrawal of patient, n (%) 0 4 (2.8) 1 (0.7) 1 (0.7)
AEs related to study drug, n (%) 16 (11.1) 8 (5.5) 19 (13.1) 16 (11.0)
Severity of study drug-related AEs, n (%)
Mild 15 (10.3) 8 (5.5) 15 (10.3) 15 (10.3)
Moderate 1 (0.7) 0 4 (2.8) 1 (0.7)
Severe 0 0 0 0
Treatment-emergency AEs (2 by preferred term), n (%)
Headache 10 (7.8) 7 (5.4) 16 (12.4) 13 (10.1)
Paresthesia 0 0 2 (1.6) 2 (1.6)
Oropharyngeal pain 1 (0.8) 2 (1.6) 1 (0.8) 1 (0.8)
Epistaxis 2 (1.6) 1 (0.8) 0 0
Nasal mucosal disorder 2 (1.6) 0 0 0
Nasopharyngitis 2 (1.6) 2 (1.6) 0 0
Upper respiratory tract infection 0 2 (1.6) 0 1 (0.8)
Herpes simplex 0 0 0 2 (1.6)
Nausea 0 0 2 (1.6) 2 (1.6)
Back pain 0 2 (1.6) 0 0
Conjunctivitis allergic 0 0 1 (0.8) 2 (1.6)
Dysmenorrhea 2 (1.6) 0 0 0
Abbreviation: AEs, adverse events.
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in TNSS ranged from 32% to 42% in the 3 S0597 groups vs just 3% in
the placebo group (Table 2). Improvements in TNSS were related
to dose, with greater decreases in TNSS observed in the highest-
dose (800-mg/d) group (P < .0001 vs placebo). The primary end
point ﬁndings were conﬁrmed in the PP population.
For the secondary efﬁcacy end point of TNSS subscales, statis-
tically signiﬁcantly greater decreases (improvements) from base-
line to days 15 and 16 in nasal congestion (P ¼ .0012 overall),
rhinorrhea (P ¼ .0011 overall), nasal itching (P ¼ .0201 overall), and
sneezing scores (P ¼ .0023 overall) were observed vs placebo in
each of the active treatment groups (eTable 1). These ﬁndings also
were observed in the PP population.
Nasal Secretion
The overall mean (SD) values for nasal secretion at baselinewere
6.65 g (4.14) in the S0597 200-mg/d group, 6.76 g (4.71) in the
400-mg/d group, 6.98 g (3.89) in the 800-mg/d group, and 5.89 g
(4.69) in the placebo group.
Therewas a statistically signiﬁcant decrease innasal secretion from
baseline to days 15 and 16 in each of the active treatment groups
compared with placebo (P < .0001 for all comparisons; Fig 2).
Decreases in nasal secretion from baseline to days 15 and 16 were
related to dose, with the highest-dosage group (800 mg/d) achieving
the greatest decreases comparedwithplacebo (day15,3.83g change
from baseline vs 0.77 g, respectively, P < .0001; day 16, 3.06 g
change from baseline vs 0.39 g, respectively, P < .0001, least-squares
mean values).
Safety
S0597 was well tolerated at all doses studied. A total of 145 AEs
were reported during the study (Table 3), most of which were mild
(68.3%) or moderate (27.6%) in intensity. One serious AE of cartilage
injury (non-nasal) occurred in a patient randomized to the S0597
400-mg/d group. This was not considered related to the study
medication.
Of the 59 AEs that were considered to be related to the drug, 19
events (32.2%) occurred in the S0597 800-mg/d group, 16 events(27.1%) occurred each in the S0597 200-mg/d and placebo groups,
and 8 events (13.6%) events occurred in the S0597 400-mg/d group.
The most commonly reported study drug-related AE was headache
(10 events in the 200-mg/d group [7.8%], 7 in the 400-mg/d group
[5.4%], 16 in the 800-mg/d group [12.4%], and 13 in the placebo
group [10.1%]).
One patient in the S0597 800-mg/d group was administered
rescue medication for mild bronchoconstriction. This was suc-
cessfully treated with a b2-agonist and the patient recovered
completely on the same day. No study-related AEs were serious or
led to death, permanent discontinuation of the study drug, or
withdrawal of the patient from the study.
No treatment-related ﬁndings were observed for vital signs,
lung function, or physical examination.Discussion
In this 15-day, randomized, placebo-controlled, double-blinded,
parallel group, single-center study, the dose-related efﬁcacy and
safety of S0597, a novel INS, were assessed in patients with SAR
using repeated grass pollen challenges in an ECC. Participants were
repeatedly exposed to grass pollen (D glomerata) in the ECC at a
concentration of 4,000 grains/m3. In a validation study using the
ECC, a dose-dependent induction of allergic symptoms was
observed when participants were exposed to pollen concentrations
of 1,000 to 8,000 grains/m3, which were noted to be within or
above the upper range of naturally occurring grass pollen in
Europe.12 Based on the results of the validation study, a concen-
tration of 4,000 grains/m3 was chosen for use in all subsequent
studies because, with this concentration, most subjects showed at
least moderate symptoms (ie, a TNNS of 6 of 12). In the area around
the Fraunhofer Institute, pollen concentrations of 2,100 grains/m3
have been measured in season.12 Although the concentration of
4,000 grains/m3 used in the present study was higher than the
natural exposure, patients developed moderate symptoms.
All 3 doses of S0597 (200, 400, and 800 mg/d) showed a signif-
icant decrease in nasal symptoms (TNSS) compared with placebo
on days 15 and 16. This also was true for the assessment of nasal
secretion, which decreased signiﬁcantly with all 3 doses of S0597
P. Badorrek et al. / Ann Allergy Asthma Immunol 115 (2015) 325e329 329compared with placebo on days 15 and 16, with the greatest
decrease observed in the highest-dose group.
A large placebo effect in TNSS was observed on day 15, with a
change from baseline of 25.2%. However, on day 16, the change
from baseline in the placebo group was only 2.9%. This placebo
effect could not be observed in the objective measurement of nasal
secretion. The amount of nasal secretion was þ15.8% on day 15
and þ58.0% on day 16 compared with baseline. The increase in
nasal secretion and decreased placebo effect on day 16 compared
with day 15 is likely due to a priming effect, which also has been
observed in other studies of repeated allergen challenges.8,9,11e13,17
In the present study, the priming effect was efﬁciently prevented by
S0597.
Interestingly, and in contrast to the objective measurement of
nasal secretion, patients in the placebo group reported a decrease
in the subjective symptom of rhinorrhea. The scores (mean  SD)
for rhinorrhea in the placebo group were 1.7  0.5 at baseline, 1.2 
0.5 on day 15, and 1.4  0.6 on day 16. This demonstrates the
importance of an objective measurement such as nasal secretion,
which can be used to support subjective results or to put them into
perspective. An additional objective measurement often used in
ECC studies is rhinomanometry, which is used to assess nasal ﬂow
and degree of nasal obstruction.18e20
Similar to other new INS therapies, S0597 was well tolerated
and demonstrated a good safety proﬁle. The most common AE of
headache did not show a relation to dose and was more frequent in
the placebo group than in the S0597 200- and 400-mg/d groups. The
high frequency of this AE probably was caused by the allergen
challenge.
Unlike some other corticosteroids, which generally act non-
selectively, S0597 has shown potent glucocorticoid receptor bind-
ing and low binding afﬁnity to other sex steroid receptors and
aldosterone.6 Furthermore, in preclinical models, S0597 has shown
local anti-inﬂammatory activity, low oral bioavailability, and low
potential for systemic adverse effects, leading to a high therapeutic
index.6 These ﬁndings together with the present results suggest
that S0597 compares favorably with existing INS therapies in efﬁ-
cacy and side effects. However, further studies are needed to make
head-to-head comparisons.
In conclusion, this study demonstrated that all 3 tested doses of
S0597were safe, well tolerated, and showed a signiﬁcant treatment
beneﬁt compared with placebo in decreasing the symptoms of SAR
in adult patients. Additional clinical trials are needed to assess
whether S0597 also is suitable as a once-daily treatment.
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eTable 1
Change in total nasal symptom score subscales from baseline to day 15 and day 16 (intent-to-treat population)
S0597 Placebo (n ¼ 39) P value
200 mg/d (n ¼ 39) 400 mg/d (n ¼ 37) 800 mg/d (n ¼ 39)
Nasal congestion .0012
Change from baseline to day 15, LSM (SE) 0.84 (0.084) 0.79 (0.087) 0.85 (0.084) 0.52 (0.085)
Change from baseline to day 16, LSM (SE) 0.71 (0.089) 0.66 (0.094) 0.81 (0.090) 0.30 (0.090)
P value for pairwise comparisona .0012 .0078 .0003 d d
Rhinorrhea .0011
Change from baseline to day 15, LSM (SE) 0.61 (0.074) 0.63 (0.076) 0.68 (0.074) 0.38 (0.075)
Change from baseline to day 16, LSM (SE) 0.47 (0.077) 0.38 (0.080) 0.56 (0.078) 0.10 (0.077)
P value for pairwise comparisona .0022 .0083 .0002 d d
Nasal itching .0201
Change from baseline to day 15, LSM (SE) 0.61 (0.079) 0.63 (0.082) 0.69 (0.079) 0.48 (0.079)
Change from baseline to day 16, LSM (SE) 0.48 (0.086) 0.54 (0.090) 0.62 (0.087) 0.16 (0.087)
P value for pairwise comparisona .0356 .0204 .0032 d d
Sneezing .0023
Change from baseline to day 15, LSM (SE) 0.43 (0.068) 0.57 (0.070) 0.53 (0.068) 0.34 (0.068)
Change from baseline to day 16, LSM (SE) 0.33 (0.080) 0.44 (0.083) 0.49 (0.081) 0.01 (0.080)
P value for pairwise comparisona .0356 .0008 .0011 d d
Abbreviation: LSM, least-squares mean.
aSigniﬁcant paired treatment difference vs placebo (by the Student t test).
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